The expiration of Germany's 16% rebate for pharmaceuticals at the end of 2013 is prompting debate about its necessity. The country's Statutory Health Insurance funds, which benefit from the rebate, made a huge surplus last year, according to price consultant Andreas Guhl. Contracts will expire Dec. 31, so a decision will likely be made about August to October. "I can't see the likelihood of the rebate disappearing completely," Guhl said.
Published in Brief: